Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Methodological consensus on clinical proton MRS of the brain: Review and recommendations
Wilson, Martin , Andronesi, Ovidiu C. , Barker, Peter B. , Bartha, Robert , Bizzi, Alberto , Bolan, Patrick J. , Cudalbu, Cristina , Dydak, Ulrike , Emir, Uzay E. , González, R. Gilberto , Gruber, Stephan , Gupta, Rakesh K. , Henning, A , Hetherington, Hoby P. , Hüppi, Petra S. , Hurd, Ralph E. , Kantarci, Kejal , Kauppinen, Risto A. , Klomp, Dennis W. J. , Kreis, Roland , Kruiskamp, Marijn J., Leach, Martin O. , Lin, Alexander , Luijten, Peter R. , Marjańska, Małgorzata , Meyerhoff, Dieter J. , Mountford, Carolyn E. , Mullins, Paul G. , Murdoch, James B. , Nelson, Sarah J. , Noeske, Ralph , Öz, Gülin , Pan, Julie W., Poptani, Harish , Posse, Stefan , Ratai, Eva‐Maria , Salibi, Nouha , Scheenen, Tom W. J. , Soher, Brian J. , Tkáč, Ivan , Vigneron, Daniel B. , Howe, Franklyn A. , Choi, In‐Young , Kreis, Roland , Maudsley, Andrew A , Howe, Franklyn A , Öz, Gülin , Marjańska, Małgorzata , Kantarci, Kejal , Brindle, Kevin Michael , Choi, In‐Young, Gruetter, Rolf , Heerschap, Arend , Peet, Andrew C. , Smith, Ian C. P.

Mayo Clinic

Magnetic Resonance in Medicine | March 28, 2019 | Volume: 82 | Issue: 2 | Pages: 527-550

10.1002/mrm.27742 | PMID 30919510 Get It

Proton MRS (1H MRS) provides noninvasive, quantitative metabolite profiles of tissue and has been shown to aid the clinical management of several brain diseases. Although most modern clinical MR scanners support MRS capabilities, routine use is largely restricted to specialized centers with good access to MR research support. Widespread adoption has been slow for several reasons, and technical challenges toward obtaining reliable good‐quality results have been identified as a contributing factor. Considerable progress has been made by the research community to address many of these challenges, and in this paper a consensus is presented on deficiencies in widely available MRS methodology and validated improvements that are currently in routine use at several clinical research institutions. In particular, the localization error for the PRESS localization sequence was found to be unacceptably high at 3 T, and use of the semi‐adiabatic localization by adiabatic selective refocusing sequence is a recommended solution. Incorporation of simulated metabolite basis sets into analysis routines is recommended for reliably capturing the full spectral detail available from short TE acquisitions. In addition, the importance of achieving a highly homogenous static magnetic field (B0) in the acquisition region is emphasized, and the limitations of current methods and hardware are discussed. Most recommendations require only software improvements, greatly enhancing the capabilities of clinical MRS on existing hardware. Implementation of these recommendations should strengthen current clinical applications and advance progress toward developing and validating new MRS biomarkers for clinical use.
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma
Trippa, Lorenzo , Gaffey, Sarah, Arrillaga‐Romany, Isabel , Lee, Eudocia Q. , Rinne, Mikael L. , Ahluwalia, Manmeet S. , Colman, Howard , Fell, Geoffrey, Lassman, Andrew B. , Meredith, David M. , Schiff, David , Welch, Mary , Wen, Patrick Y. , Galanis, Evanthia , Ahluwalia, Manmeet S , Alexander, Brian M. , Arrillaga‐Romany, Isabel , Colman, Howard , Fell, Geoffrey G. , Groot, John de , Drappatz, Jan , Nabors, Burt , Santagata, Sandro , Ligon, Keith L , Wen, Patrick Yung

Mayo Clinic

JCO Precision Oncology | March 27, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-13

10.1200/po.18.00071 | PMID 32914038 Get It

PURPOSE Adequately prioritizing the numerous therapies and biomarkers available in late-stage testing for patients with glioblastoma (GBM) requires an efficient clinical testing platform. We developed and implemented INSIGhT (Individualized Screening Trial of Innovative Glioblastoma Therapy) as a novel adaptive platform trial (APT) to develop precision medicine approaches in GBM. METHODS INSIGhT compares experimental arms with a common control of standard concurrent temozolomide and radiation therapy followed by adjuvant temozolomide. The primary end point is overall survival. Patients with newly diagnosed unmethylated GBM who are IDH R132H mutation negative and with genomic data available for biomarker grouping are eligible. At the initiation of INSIGhT, three experimental arms (neratinib, abemaciclib, and CC-115), each with a proposed genomic biomarker, are tested simultaneously. Initial randomization is equal across arms. As the trial progresses, randomization probabilities adapt on the basis of accumulating results using Bayesian estimation of the biomarker-specific probability of treatment impact on progression-free survival. Treatment arms may drop because of low probability of treatment impact on overall survival, and new arms may be added. Detailed information on the statistical model and randomization algorithm is provided to stimulate discussion on trial design choices more generally and provide an example for other investigators developing APTs. CONCLUSION INSIGhT (NCT02977780) is an ongoing novel biomarker-based, Bayesian APT for patients with newly diagnosed unmethylated GBM. Our goal is to dramatically shorten trial execution timelines while increasing scientific power of results and biomarker discovery using adaptive randomization. We anticipate that trial execution efficiency will also be improved by using the APT format, which allows for the collaborative addition of new experimental arms while retaining the overall trial structure.
Molecular and Cytogenetic Education in Hematopathology Fellowship
Soma, Lorinda, Kovach, Alexandra E. , Siddon, Alexa J. , Beck, Rose , Wu, David , Cook, James R. , Prakash, Sonam , Rosado, Flavia, Bradley, Kyle T., Weinberg, Olga K. , Sargent, Rachel L. , Gibson, Sarah E. , Kovach, Alexandra E , Swerdlow, Steven H. , Kim, Annette S , Jones, Dan M. , Crane, Genevieve M.

Mayo Clinic

American Journal of Clinical Pathology | March 26, 2019 | Volume: 152 | Issue: 4 | Pages: 438-445

10.1093/ajcp/aqz048 | PMID 31141139 Get It

Abstract Objectives Given the increased complexity of molecular and cytogenetic testing (MOL-CG), the Society for Hematopathology Education Committee (SH-EC) was interested in determining what the current expectations are for MOL-CG education in hematopathology (HP) fellowship training. Methods The SH-EC sent a questionnaire to HP fellowship program directors (HP-PDs) covering MOL-CG training curricula, test menus, faculty background, teaching, and sign-out roles. These findings were explored via a panel-based discussion at the 2018 SH-EC meeting for HP-PDs. Results HP fellows are expected to understand basic principles, nomenclature, and indications for and limitations of testing. Interpretation of common assays is within that scope, but not necessarily proficiency in technical troubleshooting of testing or analysis of complex raw data. Conclusions The consensus was that HP fellows should understand the components of MOL-CG testing necessary to incorporate those results into an accurate, clinically relevant, and integrated HP report.
Postoperative Hardware-Related Infection from Kytococcus schroeteri: Its Association with Prosthetic Material and Hematological Malignancies—A Report of a Case and Review of Existing Literature
Shah, Aditya , Vijayvargiya, Prakhar , Jung, Sarah , Wilson, John , Shah, Aditya S

Mayo Clinic

Case Reports in Infectious Diseases | March 24, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-4

10.1155/2019/6936472 | PMID 31019817 Get It

Introduction. Kytococcus schroeteri is an infrequently isolated Gram-positive coccus often encountered as a commensal bacterium. Only eighteen cases of human infection associated with this organism have been previously reported. Most of these cases involved patients with implanted prosthetic materials or patients with immunosuppressive conditions. It has been described in prosthetic valve endocarditis and in select patients with hematologic diseases but only one prior report as being involved in osteoarticular infections. Case Presentation. We describe a case of postsurgical osteoarticular hardware-related infection by K. schroeteri and discuss a possible association with implanted prosthetic material. Conclusion. Other clinical presentations of K. schroeteri, including reported infection syndromes, antimicrobial susceptibility profiles, and treatment outcomes, are also reviewed.
Clinicopathological, immunophenotypic and genetic studies of mediastinal paragangliomas†
Hsu, Ying-Han R, Torres‐Mora, Jorge , Kipp, Benjamin R. , Sukov, William R. , Jenkins, Sarah M. , Voss, Jesse S. , Cassivi, Stephen D. , Roden, Anja C. , Barr Fritcher, Emily G, Hsu, Ying-Han R. , Fritcher, Emily G. Barr , Schaff, Hartzell V.

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | March 21, 2019 | Volume: 56 | Issue: 5 | Pages: 867-875

10.1093/ejcts/ezz115 | PMID 31329844 Get It

Abstract OBJECTIVES Paragangliomas have unique features in the mediastinum, in part due to their location. Because of their paucity, they have not been thoroughly investigated. We studied the clinical, pathological, immunohistochemical and molecular features of mediastinal paragangliomas. METHODS Immunohistochemistry, next-generation sequencing mutation panel and the Oncoscan assay were performed. RESULTS Twenty-four patients with mediastinal paraganglioma (7 men, 29.2%) had a median age of 45.5 years (19.8–72.2). Twenty-one (87.5%) paragangliomas were completely resected. Six (of 24, 25.0%) tumours were considered metastatic. Mitotic activity occurred in 11 (of 24, 45.8%) paragangliomas. Programmed death-ligand 1 (PD-L1) (n = 23) was expressed in 6 (26%) patients in 10% (n = 2) and 1% (n = 4) of tumour cells, respectively. SDHB expression was lost in 19 (of 22, 86.4%) cases. ATRX expression was lost in 11 (of 23, 47.8%) cases. Next-generation sequencing revealed a single pathogenic mutation in 10 (of 19) specimens including SDHB (n = 4), SDHD (n = 6), SDHC (n = 1), ATRX (n = 1), and ≥2 mutations in 2 cases [SDHC and TERT (n = 1); SDHB, ATRX and TP53 (n = 1)]. Germline mutation analysis revealed the same succinate dehydrogenase mutation (or lack thereof) as identified in the paraganglioma in 11 (of 12) cases. During a median follow-up (n = 21) of 4.8 years (0.8–14.9), 3 patients developed metastases; 4 patients died, at least 1 of disease. CONCLUSIONS Mediastinal paragangliomas can be associated with morbidity and mortality. Many mediastinal paragangliomas have been reported to be associated with syndromes such as multiple endocrine neoplasia, von Hippel-Lindau or succinate dehydrogenase syndrome with mutation profiles dominated by alterations in genes associated with these syndromes.
Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019
Tempero, Margaret A. , Malafa, Mokenge P. , Chiorean, E Gabriela, Czito, Brian G. , Scaife, Courtney, Narang, Amol K, Fountzilas, Christos, Wolpin, Brian M. , Al-Hawary, Mahmoud, Asbun, Horacio, Behrman, Stephen W. , Benson, Al B. , Binder, Ellen, Cardin, Dana B, Cha, Charles, Chung, Vincent, Dillhoff, Mary, Dotan, Efrat, Ferrone, Cristina R, Fisher, George, Hardacre, Jeffrey, Ko, Andrew H. , LoConte, Noelle, Lowy, Andrew M, Moravek, Cassadie, Nakakura, Eric K. , O'Reilly, Eileen M, Obando, Jorge, Reddy, Sushanth, Thayer, Sarah P. , Wolff, Robert A. , Burns, Jennifer L, Zuccarino-Catania, Griselda, LoConte, Noelle K. , Chung, Vincent , Cardin, Dana B. , O’Reilly, Eileen M. , Fountzilas, Christos , Cha, Charles , Cardin, Dana B , LoConte, Noelle , O'Reilly, Eileen M , Chung, Vincent , Chiorean, E Gabriela, Scaife, Courtney, Narang, Amol K, Fountzilas, Christos, Al-Hawary, Mahmoud, Asbun, Horacio, Binder, Ellen, Cardin, Dana B, Cha, Charles, Chung, Vincent, Dillhoff, Mary, Dotan, Efrat, Ferrone, Cristina R, Fisher, George, Hardacre, Jeffrey, Hawkins, William G , LoConte, Noelle, Lowy, Andrew M, Moravek, Cassadie, O'Reilly, Eileen M, Reddy, Sushanth, Burns, Jennifer L, Zuccarino-Catania, Griselda

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 20, 2019 | Volume: 17 | Issue: 3 | Pages: 202-210

10.6004/jnccn.2019.0014 | PMID 30865919 Get It

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights discuss important updates to the 2019 version of the guidelines, focusing on postoperative adjuvant treatment of patients with pancreatic cancers.
Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival
Baraghoshi, David , Garrido‐Laguna, Ignacio , Gilcrease, Glynn Weldon, Whisenant, Jonathan, Weis, John R., Scaife, Courtney L. , Pickron, T. Bartley, Huang, Lyen C. , Monroe, Marcus M. , Abdelaziz, Sarah, Fraser, Alison , Deshmukh, Vikrant , Rowe, Kerry , Snyder, John , Samadder, N. Jewel , Hashibe, Mia, Samadder, Niloy J, Lloyd, Shane , Tao, Randa , Smith, Ken R. , Newman, Michael , Snyder, John

Mayo Clinic

American Journal of Clinical Oncology | March 18, 2019 | Volume: 42 | Issue: 4 | Pages: 355-362

10.1097/coc.0000000000000529 | PMID 30844850 Get It

Objectives: To determine the risk and risk factors for mental illness among colorectal cancer (CRC) survivors across short-term and long-term follow-up periods. Methods: We used the Utah Cancer Registry to identify CRC survivors diagnosed between 1997 and 2013. Mental health diagnoses were available in electronic medical records and statewide facilities data that were linked by the Utah Population Database. CRC survivors were matched to individuals from a general population cohort. The risk of developing a mental illness was compared between cohorts. The association between mental illness and mortality was also analyzed. Results: In total, 8961 CRC survivors and 35,897 individuals in a general population cohort were identified. CRC survivors were at increased risk for any mental health diagnosis at 0 to 2 years (hazard ratio [HR], 3.70; 95% confidence interval [CI], 3.47-3.95), >2 to 5 years (HR, 1.23; 95% CI, 1.09-1.38), and >5 years (HR, 1.20; 95% CI, 1.07-1.36) after cancer diagnosis. CRC survivors were also at increased risk of depressive disorders specifically during the same time periods. At >5 years, CRC survivors still had an increased risk of developing many mental health diagnoses. Factors associated with increased risk of any mental health disorder among CRC survivors included colostomy and Charlson Comorbidity Index of 1+. There was an increased risk of death for CRC survivors diagnosed with any mental health disorder (HR, 2.18; 95% CI, 2.02-2.35) and depression (HR, 2.10; 95% CI, 1.92-2.28). Conclusions: CRC survivors are at increased risk for mental health disorders in the short-term and long-term. Survivors who develop mental health disorders also experience decreased survival.
Catecholamine and Metanephrine Levels in Breast Milk Before and After Paraganglioma Resection
Dodd, Sarah E. , Martin, Yvette N. , Singh, Ravinder J.

Mayo Clinic

Breastfeeding Medicine | March 15, 2019 | Volume: 14 | Issue: 4 | Pages: 276-277

10.1089/bfm.2019.0018 | PMID 30874459 Get It

Quantitative analysis of nonvisit care activities performed by ambulatory care pharmacists in the outpatient primary care clinic setting
Tarpenning, Kimberly A. Kosloski , McGill, Sarah A., Yost, Kaitlin J. , Tumerman, Marc , Peterson, Jessica A.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | March 13, 2019 | Volume: 2 | Issue: 6 | Pages: 645-651

10.1002/jac5.1094 Get It

IntroductionThe value of pharmacists as direct patient care providers in integrated ambulatory care teams has been demonstrated. As the reimbursement landscape changes, patient care outside of office visits is increasing through nonvisit care.ObjectiveWe aimed to quantify the time spent by ambulatory care pharmacists on nonvisit care activities in the outpatient primary care clinic setting.MethodsData were collected from four outpatient ambulatory care practices in our institution over 12 weeks. The primary objective was to quantify the time spent performing nonvisit care activities. Secondary objectives were to quantify the number of patients affected, the number of nonvisit care activities, the types of medication therapy problems (MTPs) encountered during nonvisit care activities, and the resulting medication therapy interventions.ResultsA total of 1311 patients were affected during the study, and pharmacists spent a daily average of 1.6 hours performing nonvisit patient care. Among 1548 nonvisit care activities, staff face‐to‐face curbside consult was the most frequent (41%). Among 1866 MTPs identified (1.4 MTP per patient), the most common problems identified were need for education (31%), adverse medication events (21%), need for an additional medication (20%), and nonadherence (12%). The most common interventions were health care team education (28%), recommendation to switch medication (18%), patient education (17%), and start a new medication (14%).ConclusionAmbulatory care pharmacists spent considerable time performing nonvisit care, with multiple MTPs identified during these encounters. Health care teams frequently used pharmacists for nonvisit patient care. Further research is needed to determine the best utilization of pharmacist resources allocated to nonvisit care in an integrated ambulatory care practice.